Patents by Inventor Michael William Wilson

Michael William Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused bicyclic metalloproteinase inhibitors
    Publication number: 20040034054
    Abstract: The present invention relates to fused bicyclic metalloproteinase inhibitors of the formula 1
    Type: Application
    Filed: August 5, 2003
    Publication date: February 19, 2004
    Inventor: Michael William Wilson
  • Benzo thiadiazine matrix metalloproteinase inhibitors
    Patent number: 6656932
    Abstract: Selective MMP-13 inhibitors are benzo thiadiazines of the Formula or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen or alkyl; R1 and R3 include hydrogen, alkyl, and aryl, with the proviso that R3 is not (CH2)m biphenyl or (CH2)m substituted biphenyl; X is O or NH, n is 0, 1, or 2. The compounds of Formula I, or a pharmaceutically acceptable salt thereof, is useful for treating diseases mediated by an MMP-13 enzyme, including diseases selected from osteoarthritis, rheumatoid arthritis, cancer, inflammation, and heart failure.
    Type: Grant
    Filed: February 13, 2002
    Date of Patent: December 2, 2003
    Assignee: Warner-Lambert Company
    Inventors: Joseph Armand Picard, Michael William Wilson
  • Alkynylated fused ring pyrimidine compounds
    Publication number: 20030130278
    Abstract: A compound selected from those of formula (I): 1
    Type: Application
    Filed: October 11, 2002
    Publication date: July 10, 2003
    Inventors: Bernard Gaudilliere, Henri Jacobelli, Joseph Armand Picard, Michael William Wilson
  • Thiazolidinone compounds useful as chemokine inhibitors
    Patent number: 6506751
    Abstract: Disclosed are compounds of the Formula I wherein: Z is C or nothing, provided that when Z is nothing, R3 and R4 are nothing; A is S, S═O or O═S═O; R1 and R2 are independently hydrogen, lower alkyl, halogen, hydroxy or lower alkoxy, (un)substituted aryl, (un)substituted arylalkyl, (un)substituted heteroaryl or(un)substituted heteroarylakyl; R3 and R4 independently represent hydrogen, lower alkyl, cycloalkyl, aminoalkyl, mono- or dialkylaminoalkyl, (un)substituted aryl or (un)substituted heteroaryl; R5 represents a (un)substituted carbocyclic group containing from 3-7 members, up to two of which members are optionally hetero atoms; or R5 is (CR6R7)—(CH2)n—XR8R9; X is S or N; R6, R7, R8, R9, and n are as defined in the specification. The compounds are useful in the treatment and prevention of the AIDS virus. Intermediates useful in the preparation of the final products, pharmaceutical compositions containing the final products are also taught.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: January 14, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Stephanie Elizabeth Ault Justus, Helen Tsenwhei Lee, Jason Keith Pontrello, Bruce David Roth, Karen Elaine Sexton, Michael William Wilson
  • Quinazolines as MMP-13 inhibitors
    Publication number: 20020193377
    Abstract: A compound selected from those of formula (I): 1
    Type: Application
    Filed: February 13, 2002
    Publication date: December 19, 2002
    Inventors: Charles Andrianjara, Nicole Chantel Barvian, Bernard Gaudilliere, Henri Jacobelli, Daniel Fred Ortwine, William Chester Patt, Ly Pham, Catherine Rose Kostlan, Michael William Wilson
  • Pyridine matrix metalloproteinase inhibitors
    Publication number: 20020161000
    Abstract: Selective MMP-13 inhibitors are pyridine derivatives of the formula 1
    Type: Application
    Filed: February 8, 2002
    Publication date: October 31, 2002
    Inventors: Nicole Chantel Barvian, David Thomas Connor, Patrick Michael O'Brien, Daniel Fred Ortwine, William Chester Patt, Kevon Ray Shuler, Michael William Wilson
  • Benzo thiadiazine matrix metalloproteinase inhibitors
    Publication number: 20020156069
    Abstract: Selective MMP-13 inhibitors are benzo thiadiazines of the Formula 1
    Type: Application
    Filed: February 13, 2002
    Publication date: October 24, 2002
    Inventors: Joseph Armand Picard, Michael William Wilson
  • Agents acting at cholecystokinin receptors
    Patent number: 6103761
    Abstract: The invention concerns a series of novel bis-urea derivatives, nonpeptides, which show good binding affinity for the CCK-B receptor. The compounds, compositions containing them, methods of preparation, and utilities including anxiety, gastric acid secretion inhibition, and psychoses are included.
    Type: Grant
    Filed: October 19, 1994
    Date of Patent: August 15, 2000
    Assignee: Warner-Lambert Company
    Inventors: Bradley Dean Tait, Michael William Wilson
  • Substituted DI- and tripeptide inhibitors of protein: farnesyl transferase
    Patent number: 5830868
    Abstract: Novel inhibitors of protein:farnesyl transferase enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling tissue proliferative diseases, including cancer and restenosis.
    Type: Grant
    Filed: June 27, 1996
    Date of Patent: November 3, 1998
    Assignee: Warner-Lambert Company
    Inventors: Gary Louis Bolton, Mark Wallace Creswell, John Cooke Hodges, Michael William Wilson